Cambridge, United Kingdom
Evonetix Ltd, founded in 2015, is a prominent player in the Biopharma, Biotechnology, and Life Sciences industries, headquartered in the United Kingdom. Their slogan, "Technology to ignite the biology revolution," aptly encapsulates their mission. The company's innovative desktop DNA synthesis platform promises to revolutionize gene synthesis by enabling synthesis with unprecedented accuracy, scale, and speed. This technological leap is set to significantly enhance the capabilities of synthetic biology, allowing scientists to work at scales previously unachievable.
In their latest financial milestone, Evonetix Ltd secured a substantial £20.00M Series B investment on 07 February 2023. This round saw participation from renowned investors including Civilization Ventures, DCVC, Molten Ventures, Cambridge Consultants, Foresite Capital, Page One Ventures, Providence Investment Company Limited, and Morningside Group. This investment underscores market confidence in Evonetix's groundbreaking approach to DNA synthesis and its potential to drive the future of synthetic biology.
ELEGEN
